Skinvisible, Inc. (SKVI) stock
SKVIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.16+0.00 (+0.06%)
Close on Oct 19, 2026Market cap $843.54KP/E –Yield –
Skinvisible operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Skinvisible's operating income for the twelve months ending Jun 30, 2026 was -$458.98K. For fiscal 2025 it was -$496.32K. The highest annual figure on record is $188.08K in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$496.32K | – |
| FY2024 | Dec 31, 2024 | -$589.59K | – |
| FY2023 | Dec 31, 2023 | -$490.38K | – |
| FY2022 | Dec 31, 2022 | -$238.43K | -226.8% |
| FY2021 | Dec 31, 2021 | $188.08K | – |
| FY2020 | Dec 31, 2020 | -$253.67K | – |
| FY2019 | Dec 31, 2019 | -$539.78K | – |
| FY2018 | Dec 31, 2018 | -$597.94K | – |
| FY2017 | Dec 31, 2017 | -$364.16K | – |
| FY2016 | Dec 31, 2016 | -$841.70K | – |
| FY2015 | Dec 31, 2015 | -$1.08M | – |
| FY2014 | Dec 31, 2014 | -$1.17M | – |
| FY2013 | Dec 31, 2013 | -$759.53K | – |
| FY2012 | Dec 31, 2012 | -$1.32M | – |
| FY2011 | Dec 31, 2011 | -$1.23M | – |
| FY2010 | Dec 31, 2010 | -$800.24K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$112.82K | – |
| Q1 FY2026 | Mar 31, 2026 | -$125.94K | – |
| Q4 FY2025 | Dec 31, 2025 | -$114.17K | – |
| Q3 FY2025 | Sep 30, 2025 | -$106.06K | – |
| Q2 FY2025 | Jun 30, 2025 | -$136.24K | – |
| Q1 FY2025 | Mar 31, 2025 | -$139.85K | – |
| Q4 FY2024 | Dec 31, 2024 | -$198.74K | – |
| Q3 FY2024 | Sep 30, 2024 | -$124.97K | – |
| Q2 FY2024 | Jun 30, 2024 | -$142.69K | – |
| Q1 FY2024 | Mar 31, 2024 | -$123.18K | – |
| Q4 FY2023 | Dec 31, 2023 | -$136.54K | – |
| Q3 FY2023 | Sep 30, 2023 | -$113.11K | – |
| Q2 FY2023 | Jun 30, 2023 | -$112.82K | -176.5% |
| Q1 FY2023 | Mar 31, 2023 | -$127.90K | – |
| Q4 FY2022 | Dec 31, 2022 | -$117.72K | -173.8% |
| Q3 FY2022 | Sep 30, 2022 | -$127.17K | – |
| Q4 FY2021 | Dec 31, 2021 | $147.54K | +1813.4% |
| Q3 FY2021 | Sep 30, 2021 | -$7.85K | – |
| Q2 FY2021 | Jun 30, 2021 | $159.52K | – |
| Q1 FY2021 | Mar 31, 2021 | -$111.13K | – |
| Q4 FY2020 | Dec 31, 2020 | $7.71K | – |
| Q3 FY2020 | Sep 30, 2020 | -$118.62K | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.76K | – |
| Q1 FY2020 | Mar 31, 2020 | -$129.99K | – |
| Q4 FY2019 | Dec 31, 2019 | -$117.46K | – |
| Q3 FY2019 | Sep 30, 2019 | -$136.93K | – |
| Q2 FY2019 | Jun 30, 2019 | -$139.30K | – |
| Q1 FY2019 | Mar 31, 2019 | -$146.09K | – |
| Q4 FY2018 | Dec 31, 2018 | -$153.42K | -162.5% |
| Q3 FY2018 | Sep 30, 2018 | -$138.64K | – |
| Q2 FY2018 | Jun 30, 2018 | -$131.31K | – |
| Q1 FY2018 | Mar 31, 2018 | -$174.57K | – |
| Q4 FY2017 | Dec 31, 2017 | $245.39K | – |
| Q3 FY2017 | Sep 30, 2017 | -$141.62K | – |
| Q2 FY2017 | Jun 30, 2017 | -$313.71K | – |
| Q1 FY2017 | Mar 31, 2017 | -$154.23K | – |
| Q4 FY2016 | Dec 31, 2016 | -$153.12K | – |
| Q3 FY2016 | Sep 30, 2016 | -$201.73K | – |
| Q2 FY2016 | Jun 30, 2016 | -$172.78K | – |
See a number that looks wrong?